




AMENDMENTS TO THE CLAIMS

1. (Original) A group of oligonucleotides specifically bind to human tumor necrosis factor α (TNF- α) selected from sequences showed in SEQ Nos. 1-28.

2. (Original) The oligonucleotide sequences as recited in Claim 1 including DNA sequences and RNA sequences, wherein the DNA SEQ No. 1-18 has one of the secondary structures as following:



3. (Original) The oligonucleotide sequences as recited in Claim 1, wherein the RNA SEQ No. 19-28 sequence has one of the secondary structures as following:



4. (Original) The oligonucleotide sequences as recited in Claim 1 including a homologue oligonucleotide sequence that has 70% homologue with and functions identical to the oligonucleotide sequence.

5. (Original) The oligonucleotides sequence as recited in Claim 1 including a truncated oligonucleotide sequence that functions identical to the oligonucleotide sequence.

6. (Original) The oligonucleotides sequences as recited in Claim 1 including a modified oligonucleotides sequence that functions identical to the oligonucleotides sequence.

7. (Original) A hybridizing oligonucleotides sequence which hybridize with the oligonucleotides sequence as recited in Claim 1 under strict condition.

8. (Original) A derivated oligonucleotide sequence from the oligonucleotides sequence as recited in Claim 1.

9. (Currently Amended) The application of the oligonucleotides sequence as recited in ~~any one of Claims 1, 5, 6, and 7~~ Claim 1 for manufacture for therapy and diagnosis of TNF- α related diseases.